Syncona LLP, an independent subsidiary of the Wellcome Trust, the University of Oxford, and its technology transfer arm, Isis Innovations, have announced a £12 million… Read More »New retinal gene therapy company, NightstaRx Ltd, is spun out of University of Oxford with £12M venture funding
A Seattle-based company, Acucela Inc., has raised $162.4M through the sale of 9.2M shares on the Tokyo Stock Exchange (TSE). The company was originally founded… Read More »Seattle based company, Acucela Inc., with lead geographic atrophy compound raises $162M in IPO.
French company Nicox S.A. (Euronext: COX) has announced that affiliate companies of itself and Sequenom Inc (Nicox Inc. and Sequenom Laboratories) have entered into an… Read More »French company, Nicox S.A. (Euronext: COX) announce grant of exclusive North American rights to Sequenom’s RetnaGene AMD test.
A leading Chinese venture capital firm, BCVF (formally known as BioVeda China, and headquartered in Shanghai) has invested over $7.3M (RMB 45 million) in a… Read More »Chinese venture capital group invest >$7.3M in siRNA technologies targeting ocular conditions.
Acucela, a Seattle-based clinical stage biotechnology company specialising in ophthalmic disease, has announced, as of December 27th, 2013, that it has been approved by the… Read More »Clinical stage ophthalmic company Acucela Inc., aims to raise $125M with Japanese IPO.
Pixium-Vision S.A., a privately funded Paris-based ophthalmic company, has announced the close of a EUR15 million Series A extension financing to fund the development of… Read More »French company, Pixium-Vision S.A., raises a further EUR15M in venture capital financing for retinal implant technology
Bayer Healthcare (FWB: BAYN), headquartered in Leverkusen, Germany and Versant Ventures, a life sciences venture capital company based in San Francisco, have announced an exclusive… Read More »Bayer Healthcare & Versant Ventures launch new company to develop treatments for AMD and GA
Aerpio Therapeutics, Inc., Cincinnati, Ohio, a company focused on the development of small molecules and monoclonal antibodies for the treatment of vascular disease, has announced… Read More »Aerpio Therapeutics raises $9M to progress DME trial of a tyrosine kinase receptor 2 activator
Spark Therapeutics, a new company spun out of the Children’s Hospital of Philadelphia (CHOP), has announced the launch of two gene therapy programmes following a… Read More »Spark Therapeutics launches gene therapy programmes with $50M investment
Lpath, Inc. (NASDAQ: LPTN) has announced the receipt of a notification from Pfizer Inc. that Pfizer is currently seeking to divest the company of its… Read More »Pfizer seeks to divest business interests in ophthalmology through finalising an exit agreement with LPath, Inc.